Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Rigel Pharmaceuticals)"
Count: 30
Selected: 0
| NCT ID | Title |
|---|
| NCT05308264 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | ||
| NCT04904276 | Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy | ||
| NCT04629703 | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects | ||
| NCT04138927 | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | ||
| NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA | ||
| NCT03363334 | Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP | ||
| NCT02612558 | A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) | ||
| NCT02433236 | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy | ||
| NCT02112838 | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy | ||
| NCT02077192 | Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | ||
| NCT02076412 | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | ||
| NCT02076399 | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | ||
| NCT02040623 | Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) | ||
| NCT01900249 | To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca | ||
| NCT01733992 | A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease | ||
| NCT01597050 | Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions | ||
| NCT01591044 | A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma | ||
| NCT00798096 | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma | ||
| NCT00752999 | Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus | ||
| NCT00706342 | Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) | ||
| NCT00665925 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis | ||
| NCT00665626 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) | ||
| NCT00446095 | Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma | ||
| NCT00326339 | Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1) | ||
| NCT00115089 | 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis | ||
| NCT04543279 | Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia | ||
| NCT05848258 | An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | ||
| NCT05040698 | Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa | ||
| NCT03246074 | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | ||
| NCT04581954 | Inflammatory Signal Inhibitors for COVID-19 (MATIS) |
